Related Experiment Video
Updated: Aug 8, 2025
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
291
The Proportion of Patients With Rheumatoid Arthritis Achieving ACR20/50/70; Consistent Patterns of a 60/40/20 as
Abir Mokbel, Mohammad Movahedi, Eleni Philippopoulos1
1Sidney Liswood Health Sciences Library, Mount Sinai Hospital.
Summary
Biologic treatments for rheumatoid arthritis show consistent response patterns. Biologic-naive patients achieve approximately 60% ACR20, 40% ACR50, and 20% ACR70 responses, while biologic-irresponsive patients achieve about 50% ACR20, 25% ACR50, and 12.5% ACR70.
Area of Science:
- Rheumatology
- Clinical Pharmacology
- Systematic Reviews
Background:
- Rheumatoid arthritis (RA) treatment often involves biologic disease-modifying antirheumatic drugs (bDMARDs).
- Assessing treatment efficacy using American College of Rheumatology (ACR) response criteria is crucial for patient management.
- Understanding response patterns after initial bDMARD failure is important for optimizing therapy.
Approach:
- A systematic review and meta-analysis adhering to MECIR standards was conducted.
- Two groups were analyzed: biologic-naive patients initiating bDMARDs and biologic-irresponsive (IR) patients switching to a second bDMARD.
- Randomized controlled trials comparing bDMARDs plus methotrexate (MTX) against placebo plus MTX were included.
Key Points:
- For biologic-naive RA patients, ACR20/50/70 response rates were 61.4%, 37.8%, and 18.8%, respectively.
- For biologic-IR RA patients, ACR20/50/70 response rates were 48.5%, 27.3%, and 12.9%, respectively.
- These findings suggest consistent, predictable response patterns for bDMARDs in RA.
Conclusions:
- ACR20/50/70 responses in biologic-naive RA patients follow a pattern of approximately 60%, 40%, and 20%.
- ACR20/50/70 responses in biologic-IR RA patients follow a pattern of approximately 50%, 25%, and 12.5%.
- These consistent patterns aid in predicting treatment outcomes for RA patients on bDMARDs.
More Related Videos
Related Concept Videos
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
43
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
43
01:21Rheumatic Heart Disease III: Medical Management
24
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
24
01:11Genome-wide Association Studies-GWAS
13.8K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.8K
01:23Rheumatic Heart Disease I: Introduction
25
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
25
01:20Rheumatic Heart Disease IV: Nursing Management
28
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
28
01:26Atherosclerosis III: Management
16
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16